{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-029221","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.162356+00:00","generated_at":"2026-06-22T01:47:05.241724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oncology Institute Q3 revenue $65M (+24% YoY); cuts FY2022 guidance on slower acquisitions","bullets":["Net loss $2.7M ($0.03 basic loss per share); adjusted EBITDA -$7M vs +$0.1M prior year.","Revenue guidance cut to $245-250M from $270-310M; adjusted EBITDA guidance lowered to -$28M to -$25M.","Completed $110M strategic investment via senior convertible notes from Deerfield on August 9, 2022.","Ended Q3 with 100 clinicians (+27% YoY); expanded to 14 markets with three acquisitions and two de novo clinics.","Workforce reduction and vendor cost-cutting initiated to align cost structure with revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-029221","json":"https://secwatch.observer/filing/0001628280-22-029221.json","markdown":"https://secwatch.observer/filing/0001628280-22-029221.md","text":"https://secwatch.observer/filing/0001628280-22-029221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/0001628280-22-029221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/toi-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:47:05.241724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d91ebe6454109131437e33bc3857c899f0d7a9a1","claim":"Oncology Institute, Inc. reported three months ended September 30, 2022 results: revenue $65 million, net income Net loss of $2.7 million, EPS $(0.03). Guidance raised.","evidence_excerpt":"Reger in newly created Chief Information Officer role and Cristina Green as Vice President of Clinical Research Third Quarter 2022 Financial Highlights • Consolidated revenue of $65 million, an increase of 24.3% from $52 million for the prior year quarter • Gross profit of $13 million, an increase of 13.8% compared to the prior year quarter • Net loss of $2.7","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/0001628280-22-029221-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Revenue","value":"$65 million"},{"label":"Net income","value":"Net loss of $2.7 million"},{"label":"EPS","value":"$(0.03)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}